China's crusade against pharma giants
China has taken Western pharmaceutical companies to task over alleged corruption in the country.
China's investigation into alleged corruption at pharmaceutical multi-nationals has widened in recent days. GlaxoSmithKline (GSK), accused last week of paying over $400m in bribes to doctors and lawyers to boost sales, admitted this week that senior executives "appear to have acted outside our processes and controls, which breaches Chinese law". Meanwhile, three AstraZeneca sales executives have been arrested, although the group was claiming early this week that they had no reason to believe the swoop was related to the bribery allegations.
What the commentators said
This affair is certainly starting to look like "a crusade against Western pharmaceutical giants", said Ben Griffiths in the Daily Mail. Could bribery allegations actually be designed to pressurise Western firms into cutting their prices and thus help China cope with a soaring healthcare bill? Note that GSK has now hinted at price cuts in the Chinese market.
What's more, added The Wall Street Journal, the Chinese government's investigation didn't start as a criminal matter, but as a probe into the costs of drugs made by both domestic and foreign pharma groups. A foreign firm was targeted first because "that helps distract attention from a health system that relies on corruption to stay afloat".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Hospitals are forced to keep prices for most services below cost, so drug sales is one of the few areas in which they can make money. They encourage poorly paid doctors to prescribe more drugs by linking bonuses to revenue, while doctors also get kickbacks from drug firms. But instead of changing this "dysfunctional" cause of high drug prices, concluded The Wall Street Journal, China is "taking aim" at the likes of GSK.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
8 of the best properties for sale near ski slopes
The best properties for sale near ski slopes – from a luxury cabin in Geilo, one of Norway’s premier ski resorts, to a large chalet in Valais, Switzerland
By Natasha Langan Published
-
Cash hoarders take total UK savings to £2 trillion – why aren’t we investing?
Investment-shy Brits are hoarding huge amounts of cash in their savings accounts. We look at the case for saving versus investing.
By Katie Williams Published
-
Are GSK’s legal troubles a threat to the firm’s survival?
Analysis Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargreaves looks at how it might affect the business's prospects.
By Rupert Hargreaves Published
-
GlaxoSmithKline’s first-quarter figures show the company is on track for the year
Analysis Latest results show that it's business as usual for pharmaceutical giant GlaxoSmithKline. Rupert Hargreaves casts his eyes over the numbers.
By Rupert Hargreaves Published
-
Why GSK should turn down Unilever’s billions
News Unilever has offered GSK £50bn for its consumer division. But while the cash will be a temptation, the deal is not in the interests of shareholders or of anyone else, says Matthew Lynn.
By Matthew Lynn Published
-
Unilever slides and GSK bounces after GSK knocks back £50bn bid
News Unilever shares fell to their lowest level in around five years, after its £50bn takeover bid for GSK’s consumer health unit was rejected.
By Saloni Sardana Published
-
Shake-up at GSK won’t placate investors
News GSK has launched a radical shakeup of its operations, but that's unlikely to satisfy investors unhappy with the drugmaker's perennial underperformance.
By Dr Matthew Partridge Published
-
A show of support for GlaxoSmithKline's hedge fund fight
News Several large shareholders have said that they will support GlaxoSmithKline in its battle with hedge fund Elliott Management.
By Dr Matthew Partridge Last updated
-
Activist investor Elliott takes takes a stake in Glaxo
News Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
By Dr Matthew Partridge Last updated
-
If you'd invested in: Renishaw and GlaxoSmithKline
Features Measuring-equipment maker Renishaw has seen profits leap, but investors are sceptical about the prospects for drugmaker GSK.
By Alice Gråhns Published